LGD3303 Powder


Our company is the largest API manufacturer of LGD3303 Powder in China.Our production of LGD3303 has a history of 3 years, and all production LGD3303 raw materials have a purity of more than 99% and each batch has HPLC and NMR detection reports.The LGD3303 monthly output is 15kg and the quality is stable.
The LGD3303 powder produced by our company is mainly supplied to Canada and its European market, and the customer feedback is good. Our company is a leading supplier of health care products, research institutes and fitness enthusiasts.
The LGD3303 provided by our company is powder, the color is white , the standard package is 1 kg/aluminum foil bag.We also can be divided into smaller package for the customer.The order is unlimited.After customers purchase, they can be directly processed into tablets and liquids.

It would be the best choice to cooperate with us,due to we have below advantages.
1. Professional.We has developed and produced sram series for 5 years.Rich experience in production, stable product quality, product purity up to 99%.
2. Formal business.Our company can provide HPLC, nuclear magnetic and other professional detection map for each batch of products.
3. Fast delivery. Products will send out within 24hours,delivery time is 7-10days.
4. Good service. We will provide the most thoughtful service, from procurement, quality inspection, delivery to application, etc.

LGD-3303
CAS No.:1196133-39-7
Purity: 98% 
Formule:C16H14ClF3N2O
Weight:342.74300
LGD-3303 is a drug which acts as a selective androgen receptor modulator, with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects. It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.

LGD3303 Powder quality proof(NMR and HPLC)

NMR(2018.4.2)


HPLC(2018.4.2)


LGD-3303 is a selective androgen receptor modulator (SARM) that comes with impeccable oral bioavailability. The drug is categorized as a selective agonist designed for the androgen receptor. LGD-3303 has both anabolic and androgenic effects and at the moment the drug is being researched as a possible solution to treat osteoporosis. This is a condition that leads to increased bone weakness in humans.  LGD-3303 is one of the most potent SARMs out there and for many bodybuilders who want to bulk muscle, LGD-3303 stacked with other equally effective SARMs can offer the ultimate combination.
Background
LGD-3303 is currently being developed and researched by Lingad Pharmaceuticals. The chemical structure of the drug closely reassembles that of LGD-4033 which is also another SARM that has since been developed by the same company. However, LGD-3303 is still not available in the market the same way LGD-4033 is. Trials that have been done so far on LGD-3303 show that it has the potential to significantly increase muscle mass and prevent muscle wasting. Although it can be argued that other SARMs can achieve the same thing, it is clear that LGD-3303 is a little bit more effective albeit it’s still in the development phase. LGD-3303 is a non-steroidal orally active SARM and while its effect in helping with muscle mass and increased androgenic action is huge, its effect on androgenic organs in the body in the tests subjects was very small.

The oral and infusion dose of LGD3303 powder
The rats were classified by weight and assigned to the experimental group (n=5/ group), and the operation was performed as described above. The experimental group was administered by oral administration of lgd-3303 (0.3-100mg/kg/ day) or by osmotic micro-pump (Alzetmodel2ML1).Alzet, Cupertino, CA) constant infusion lgd-3303 (dose range is 0.01-10mg/kg/day). The small pump operation was implanted into the endothelial tissue, while the rat performed ORDX under anesthesia.After 7 days, the rats were anesthetized, the operation was taken out of the small pump and replaced with a new small pump. As mentioned above, lgd-3303 is used for oral administration, and it is prepared for the micropump in 50% polyethylene glycol -400:50% dimethyl sulfoxide. In the 14th day of the experiment, the blood was collected by the jugular vein through the jugular vein, at 0,0.5,1,2,4,8,12 and 24 hours.The blood was centrifuged to measure the plasma concentration of LGD-3303.The rats were killed on the morning of the 15th day, measuring the wet weight of the ventral prostate and levator ANI.
The castration was significant, reducing the weight of the levator ANI, the weight of the abdominal prostate gland and the weight of the foreskin gland, but increasing serum LH.Lgd-3303 inhibited the effect of ORDX on the anal weight of the levator muscle at a dose of 1mg/kg/ day, and significantly increased the muscle weight above the level of eugonadal at a higher dose.LGD-3303 inhibits serum LH level in eugonadal.Lgd-3303 has a small effect on the ventral prostate and maintains a dose of 100mg/kg/ day or higher in the peritoneal prostate. Black bar, ORDX control;Solid horizontal line, sham operation control plus or minus SEM (horizontal dotted line).*, p<0.05 compared with ORDX control;+, p<0.05 compared with the complete control of sham operation through one-way ANOVA.
The distribution of LGD-3303. The rats were classified by weight and assigned to the experimental group (n=3/ group), and the surgery was performed as described above.The rats were given lgd-3303 (30mg/kg/ day) or oral gavage once a day. On the 14th day of administration, rats were killed after 2,4 or 8 hours of cardiac bleeding under isoflurane anesthesia.In the 30 minutes before the autopsy, the rat intravenous injection of 2 ml/kg was labeled with isothiocyanate (fitc-dextran, 150kDa).The weight of sigma-aldrich, st. Louis, MO) 10mg/ml high molecular weight glucan. High molecular weight fitc-glucan is slow to infiltrate and is used as a marker for blood volume in acute studies.
Immunological analysis of luteinizing hormone.
 Using the national institute of diabetes and digestive and kidney diseases (NIDDK;NationalHormoneandPeptideProgram, Dr. Parlow, Torrance, CA) reagent, through double antiserum method for determining autopsy collection of LH in serum samples. In short, the total volume of 200 samples and standard products (niddk-rlh - rp-3) were incubated at room temperature for 2 to 3 days together with the 100le primary antiserum (rabbit niddk-rlh - s-11) and diluted by 1:100,000.After that, the 100 mu l was diluted to 200,000 to 300,000 CPM /ml 125i-labeled LH (MPBiomedicals, Irvine, CA) and continued to incubate for another 24 hours. The combined hormones were separated from the free hormones by sedimentation by AntibodiesInc., Davis, CA.For this purpose, each incubation tube was added with a serum of 50 centile l4% of normal rabbit serum, and then a serum of 50 chevalier l1:10 goat antirabbit serum solution was added. The vortex tube and in 4 ℃ incubate overnight.By means of centrifugal termination measurement, the supernatant solution is poured and discarded, and it is counted and precipitated in the 10-channel renewal counter. This method has a minimum detectable quantity of 0.001ng/ tube, and the intra-batch and inter-batch variation is less than 10%.To eliminate inter-batch variability, all samples from a single study performed the same analysis.
The quantity of lgd-3303 in plasma and tissue samples. In order to determine the plasma concentration, the standard lgd-3303 solution was added into the plasma of blank rats.The calibration standard product is constructed from 0.001 to 10 carrig /ml.250 chalcole acetonitrile containing lgd-2226 was used as the internal standard (Mineretal).In 2007, the plasma samples of 50cdl and 50cdl were extracted by protein precipitation method. After centrifugation, lgd-3303 of supernatant was analyzed by liquid chromatography (LC), and then tandem mass spectrometry was performed.To determine the tissue concentration, the standard lgd-3303 solution was added to the blank rat tissue in a 2:1 ratio (v/w) of the standard solution and tissue.The calibration standard product (from 0.01-5 open g/ml) was constructed in the extraction solution containing lgd-2226 as the inner object [acetonitrile/water =70:30 (v/v)]. The tissue samples were extracted with 2 times volume containing the inner object.Lgd-3303 of supernatant was analyzed by LC series mass spectrometry after overnight extraction.AppliedBiosystemsAPI4000 or API4000/ q-trap (AppliedBiosystems, FosterCity, CA) were used for analysis by electrospray ionization mass spectrometry (MS).The samples were analyzed by injecting the supernatant of 10 to 20 centile into the LC/MS instrument. LC instrument is equipped with C8 octyl and MOS protection column (4 x 2mm;Phenomenex, Torrance, CA) and GeminiC6 - phenyl chromatographic column (50 x 2.0 mm, 5 microns;Phenomenex).The mobile phase A and B are 0.1% formic acid in H2O and 0.1% formic acid in acetonitrile respectively.Multi-reaction monitoring scanning in atomic mass units was performed in a positive mode using 343.1/245.3.
The quantity of fitc-glucan in serum and tissue samples. The serum was diluted with 1:10 in water.A 100 microliter diluted serum was removed to the micro titration plate and in the fluorescent plate reader (WallacVictor1420;PerkinElmerLifeandAnalyticalSciences, Waltham, MA) analysis to determine the concentration of FITC - glucan.The fitc-glucan was incorporated into blank serum and continuously diluted (blank serum/water, 10:90) to produce a calibration curve.Calibration samples were analyzed on the same micro titration plate as the samples to reduce variability.The serum was not exposed to light throughout the experiment.
As mentioned above, the fitc-dextran concentration in the tissue was measured after the concentration of lgd-3303.The remaining tissue and extraction solution are homogenized and centrifuged. Transfer 100 microliters of supernatant (acetonitrile/water =70:30, v/v) to a 96 hole micro titration plate.The blank prostatic and anal extracts were added to the fitc-glucan and continuously diluted to produce the calibration criteria.Establish a separate calibration curve for each organization.The calibration criteria were analyzed in the same microtitration plate as tissue samples to reduce variability.The tissue was protected by light during the whole experiment.Serum fitc-glucan concentration and local tissue fitc-glucan concentration were used to estimate the amount of tissue residual blood after cardiac hemorrhage.The residual blood volume of the tissue concentration of lgd-3303, as described above, was corrected.
The Pharmacokinetic analysis plasma samples of ORDX male rats were treated by oral gavage for 14 days with LGD-3303. After 14 days of oral administration of lgd-3303 (auc0-6) in ORDX14 male rats, exposure increased by 10 to 300mg/kg/ day. Despite increased exposure, the weight of the ventral prostate never exceeded the level of the sham surgical control and reached a significant plateau in the pharmacological response.
Pharmacokinetic analysis of LGD-3303. Use WinNonlin (version 5.0);Pharsight, MountainView, CA) analyzed plasma concentration - time data of each animal by non-compartment pharmacokinetic methods (Gibaldi and Perrier, 1982).The observed maximum concentration and corresponding sampling time are defined as Cmax and tmax respectively.The area under the plasma concentration time curve (AUC) was calculated by trapezoid method, and auc0-6 or auc0-24 were used in this.study.The half-life elimination period (t1/2) was estimated from t1/2=ln2/ indifference, and the slope of the 
How it Works
LGD-3303 has been developed to help address a wide range of conditions. However, the most important is its ability to maintain the beneficial effects of androgens in improving muscle mass and bone density without the side effects. Although the selective mechanism of LGD-3303 and other SARMs is not yet clearly understood even with ongoing research, it is clearly a big leap from the usual anabolic steroids. Once LGD-3303 is injected into the body or taken orally, it will trigger androgenic action on a cellular level.
diagram of the molecular structure for LGD-3303
However, it should be remembered that the human body contains millions of cells and a substance that triggers androgenic effects in each of these cells would have devastating side effects. That is why LGD-3303 is termed as selective. Instead of triggering androgenic action in all cells, it will only target muscle tissue and skeletal cells. This is the main reason why LGD-3303 has been used as a supplement in bodybuilding and also as a possible treatment for people who have issues with bone density. LGD-3303 could also have other positive benefits. However, because the drug is still under research, these potential benefits are not yet clear.
How it is Administered
In the test subjects that have been used to assess the potency of LGD3303 as a SARM, the drug has been administered in two ways. To start with, LGD-3303 can be injected into the blood stream.  It can also be taken orally. However, it is recommended that for humans the SARM should be taken orally. LGD-3303 comes in liquid capsules and can be taken using water or juice. The problem with using an injection is that it becomes very hard to maintain the dosage.
Advantages of using LGD-3303
Although LGD-3303 is still an experimental SARM, there are a few potential benefits that it could offer. To start with, LGD-3303 is able to offer effective androgenic action without affecting androgenic organs. This is a big plus because compared to steroids which were earlier used as substitutes for SARMs, the side effects are very minimal.
LGD-3303 has the potential to aid in increased muscle mass and bone density. For bodybuilders, this is a very important feature. While to be fair most SARMs will influence building up muscle, on the tests done so far, LGD-3303 has been very effective.
LGD-3303 has also been seen to have an effect in improving the metabolic action. This is significant in the sense that people who want to cut fat can leverage on the SARM as an aid to achieve their fat loss goals. However, stacking LGD-3303 with other equally effective SARMs and having a strong exercise regimen are important if results will be achieved.
Disadvantages of using LGD-3303
LGD-3303 is still at the trial phase and therefore it’s not easy to say whether there are any side effects or not. However, so far the review of the drug and its effect on mice have shown it has very little effect on androgenic organs.
Dosage to Be Taken
Cutting – The dosage for LGD-3303 is still being fine-tuned as research on the drug continues. However, for great effects on cutting, a dosage of between 15 mg and 20 mg for a cycle of 6 to 8 weeks is recommended.
Bulking – LGD-3303 has amazing effects on building muscle mass and in order to get results, you’ll need a dosage of between 20 mg to 30 mg per day for a cycle of 8-10 weeks.
Recomping – The same dosage for bulking will also work for recomping. 20 mg to 30 mg for a cycle of 8-10 weeks will do. However, as research on LGD-3303 continues, dosage information might also change.
Is PCT needed?
So far, research studies have shown that even as LGD-3303 delivers impeccable androgenic effects, it does not affect androgenic organs in the body. This means that it will not affect the natural production of testosterone and therefore PCT will not be needed.
Can Women Use It?
Yes, women can use LGD-3303. Remember this is not a hormone and it’s also a non-steroidal drug with no effects on androgenic organs. The risk of virilization is therefore zero.
Other SARMs That Stack Well
You can stack LGD-3303 with the following SARMs:
What is the Half-Life?
The half-life of LGD-3303 Powder is at the moment 12 hours. This means that you’ll have to use the dosage noted above twice a day for the best results.
How Long Until You See Results
It will take just a few weeks to see results but it’s best to be patient until the full cycle is done. That is when the full impact of LGD-3303 will be visible.
Will it make an Athlete Fail a Drug Test?
Yes, it is possible to fail a drug test using LGD-3303. However, because the SARM is still new, the World Anti-Doping Agency is yet to develop a test for it.



© 2018 www.whdkxs.com.All Rights Reserved